Mirati Therapeutics Inc (Mirati Therapeutics), a subsidiary of Bristol-Myers Squibb Co, is a clinical-stage oncology company. It carries out the research and development of novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics also offers MRTX1133 - pancreatic cancer and Sitravatinib - Tumor, MRTX1719 -methylthioadenosine phosphorylase (MTAP) deleted cancers and MRTX0902-solid Tumors. The company partnered with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, the Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
3545 Cray Court, San Diego, California, 92121
Website
www.mirati.com
Telephone
1 844 6472841
No of Employees
587
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$12.4M
Mirati Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| MRTX1133: Pancreatic Cancer |
| Sitravatinib: Tumor |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In January, the company received conditional marketing authorization from the European Commission for Krazati (adagrasib) to treat patients with KRASG12C-mutated advanced non-small cell lung cancer. |
| 2023 | Contracts/Agreements | In November, the company and Kura Oncology entered into a clinical collaboration and supply agreement to evaluate the combination of KO-2806 and adagrasib in patients with KRASG12C-mutated non-small cell lung cancer. |
| 2023 | Contracts/Agreements | In October, the company entered into an agreement to be acquired by Bristol Myers Squibb. |
Competitor Comparison
| Key Parameters | Mirati Therapeutics Inc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | San Diego | New Brunswick | Basel | Kenilworth | New York |
| State/Province | California | New Jersey | - | New Jersey | New York |
| No. of Employees | 587 | 131,900 | 103,605 | 72,000 | 88,000 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Charles M. Baum | Head-Research and Development; Director; President; Interim Chief Executive Officer | Executive Board | 2023 | 64 |
| Aaron Ondrey | Chief Financial Officer | Senior Management | 2023 | - |
| Betsy Gelfand | Chief Accounting Officer | Senior Management | 2023 | - |
| John Moriarty | Chief Legal Officer; Secretary | Senior Management | 2023 | - |
| Mike Paolucci | Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward